Core Insights - Abivax announced additional clinical data for obefazimod at the UEG Meeting, highlighting its efficacy in treating moderate-to-severely active ulcerative colitis [2][3] - The Phase 3 ABTECT trials demonstrated that obefazimod achieved clinically meaningful improvements across various patient subgroups, including those with prior inadequate responses to advanced therapies [4][7] Study Population - A total of 1272 patients were enrolled in the ABTECT trials, with approximately 60% having an endoscopic subscore of 3 [3] - About 47% of the total population had a prior inadequate response to advanced therapy, with 21% having failed to respond to a JAK inhibitor [3] Efficacy Results - The 50 mg dose of obefazimod showed clinically meaningful improvements in clinical remission, with a placebo-adjusted difference of 10% for patients with prior inadequate response (p=0.0009) and 22% for those without (p<0.0001) [4][7] - In participants without prior inadequate response, the 50 mg dose achieved a placebo-adjusted difference in clinical response of 28% (p<0.0001), while those with four or more prior inadequate responses showed a 29% difference (p=0.0242) [4][7] - The treatment also demonstrated a 34% improvement in clinical response for participants who previously failed JAK inhibitor therapy (p=0.0017) [4][7] Safety Profile - Obefazimod was well tolerated, with no new safety signals identified for both the 25 mg and 50 mg doses [4][7] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [9]